June 13 (UPI) -- England's National Health Service said Friday it is the first health system in the world to offer a targeted blood cancer therapy that can stop progression of the cancer for nearly three times as long existing treatments. Known as a "trojan horse' therapy, belantamab mafodotin was approved Thursday for treating multiple myeloma. The NHS said in a statement, "Belantamab mafadotin -- which was research and developed in the UK -- is an antibody-drug conjugate, a type of treatment